These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

469 related articles for article (PubMed ID: 17312847)

  • 1. [Hyperhomocysteinemia in pediatric age and nutritional aspects of folates: an early cardiovascular risk factor].
    Caramia G; Belardinelli R
    Monaldi Arch Chest Dis; 2006 Dec; 66(4):275-85. PubMed ID: 17312847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DACH-LIGA homocystein (german, austrian and swiss homocysteine society): consensus paper on the rational clinical use of homocysteine, folic acid and B-vitamins in cardiovascular and thrombotic diseases: guidelines and recommendations.
    Stanger O; Herrmann W; Pietrzik K; Fowler B; Geisel J; Dierkes J; Weger M;
    Clin Chem Lab Med; 2003 Nov; 41(11):1392-403. PubMed ID: 14656016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical use and rational management of homocysteine, folic acid, and B vitamins in cardiovascular and thrombotic diseases.
    Stanger O; Herrmann W; Pietrzik K; Fowler B; Geisel J; Dierkes J; Weger M
    Z Kardiol; 2004 Jun; 93(6):439-53. PubMed ID: 15252738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperhomocysteinemia and cardiovascular risk: effect of vitamin supplementation in risk reduction.
    Ciaccio M; Bellia C
    Curr Clin Pharmacol; 2010 Feb; 5(1):30-6. PubMed ID: 20236081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Homocysteine and cardiovascular disease: a review of the evidence.
    Wierzbicki AS
    Diab Vasc Dis Res; 2007 Jun; 4(2):143-50. PubMed ID: 17654449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Homocysteine lowering and cardiovascular disease risk: lost in translation.
    Marcus J; Sarnak MJ; Menon V
    Can J Cardiol; 2007 Jul; 23(9):707-10. PubMed ID: 17622392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Hyperhomocysteinemia and cardiometabolic risk].
    Vannucchi H; Melo SS
    Arq Bras Endocrinol Metabol; 2009 Jul; 53(5):540-9. PubMed ID: 19768245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Homocysteine, endothelial dysfunction and cardiovascular risk: pathomechanisms and therapeutic options].
    Sydow K; Böger RH
    Z Kardiol; 2001 Jan; 90(1):1-11. PubMed ID: 11220081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The homocysteine hypothesis: still relevant to the prevention and treatment of cardiovascular disease?
    Abraham JM; Cho L
    Cleve Clin J Med; 2010 Dec; 77(12):911-8. PubMed ID: 21147945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of long-term homocysteine reduction with B vitamins on arterial wall inflammation assessed by fluorodeoxyglucose positron emission tomography: a randomised double-blind, placebo-controlled trial.
    Potter K; Lenzo N; Eikelboom JW; Arnolda LF; Beer C; Hankey GJ
    Cerebrovasc Dis; 2009; 27(3):259-65. PubMed ID: 19202330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emergent cardiovascular risk factor: homocysteine.
    Warren CJ
    Prog Cardiovasc Nurs; 2002; 17(1):35-41. PubMed ID: 11872979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Homocysteine--a risk factor for atherosclerosis].
    Debreceni L
    Orv Hetil; 2001 Jul; 142(27):1439-44. PubMed ID: 11481906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Total homocysteine concentration and associated cardiovascular and renal implications in adults.
    Bergen C; Compher C
    J Cardiovasc Nurs; 2006; 21(1):40-6. PubMed ID: 16407736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Disturbances of homocysteine metabolism as a risk factor of cardiovascular diseases development: effect on prognosis and possibilities of correction with drugs].
    Shakhmatova OO; Komarov AL; Panchenko EP
    Kardiologiia; 2010; 50(1):42-50. PubMed ID: 20144157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationale, design and baseline characteristics of a large, simple, randomized trial of combined folic acid and vitamins B6 and B12 in high-risk patients: the Heart Outcomes Prevention Evaluation (HOPE)-2 trial.
    Lonn E; Held C; Arnold JM; Probstfield J; McQueen M; Micks M; Pogue J; Sheridan P; Bosch J; Genest J; Yusuf S;
    Can J Cardiol; 2006 Jan; 22(1):47-53. PubMed ID: 16450017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Homocysteine and diabetic macroangiopathy].
    Araki A
    Nihon Rinsho; 2006 Nov; 64(11):2153-8. PubMed ID: 17087311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vitamin supplements and cardiovascular risk: review of the randomized trials of homocysteine-lowering vitamin supplements.
    Clarke R; Armitage J
    Semin Thromb Hemost; 2000; 26(3):341-8. PubMed ID: 11011852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of B vitamins status and homocysteine levels in elderly Taiwanese.
    Chen KJ; Pan WH; Yang FL; Wei IL; Shaw NS; Lin BF
    Asia Pac J Clin Nutr; 2005; 14(3):250-5. PubMed ID: 16169836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vitamins and minerals 4: overview of folate and the B vitamins.
    Thompson J
    Community Pract; 2006 Jun; 79(6):197-8. PubMed ID: 16780289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: a randomized controlled trial.
    Ebbing M; Bleie Ø; Ueland PM; Nordrehaug JE; Nilsen DW; Vollset SE; Refsum H; Pedersen EK; Nygård O
    JAMA; 2008 Aug; 300(7):795-804. PubMed ID: 18714059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.